- Home
- BFRG vs HOOK Comparison
BFRG vs HOOK Comparison
Compare BFRG & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFRG
- HOOK
- Stock Information
- Founded
- BFRG 2017
- HOOK 2011
- Country
- BFRG United States
- HOOK United States
- Employees
- BFRG N/A
- HOOK 87
- Industry
- BFRG Retail: Computer Software & Peripheral Equipment
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- BFRG Technology
- HOOK Health Care
- Exchange
- BFRG Nasdaq
- HOOK Nasdaq
- Market Cap
- BFRG 16.4M
- HOOK 11.9M
- IPO Year
- BFRG 2023
- HOOK 2019
- Fundamental
- Price
- BFRG $1.51
- HOOK $0.92
- Analyst Decision
- BFRG
- HOOK Buy
- Analyst Count
- BFRG 0
- HOOK 4
- Target Price
- BFRG N/A
- HOOK $10.67
- AVG Volume (30 Days)
- BFRG 204.8K
- HOOK 113.6K
- Earning Date
- BFRG 08-06-2025
- HOOK 08-07-2025
- Dividend Yield
- BFRG N/A
- HOOK N/A
- EPS Growth
- BFRG N/A
- HOOK N/A
- EPS
- BFRG N/A
- HOOK N/A
- Revenue
- BFRG N/A
- HOOK $9,351,000.00
- Revenue This Year
- BFRG N/A
- HOOK N/A
- Revenue Next Year
- BFRG N/A
- HOOK N/A
- P/E Ratio
- BFRG N/A
- HOOK N/A
- Revenue Growth
- BFRG N/A
- HOOK N/A
- 52 Week Low
- BFRG $1.23
- HOOK $0.72
- 52 Week High
- BFRG $4.84
- HOOK $6.46
- Technical
- Relative Strength Index (RSI)
- BFRG 49.22
- HOOK 21.63
- Support Level
- BFRG $1.44
- HOOK $0.90
- Resistance Level
- BFRG $1.58
- HOOK $1.16
- Average True Range (ATR)
- BFRG 0.07
- HOOK 0.07
- MACD
- BFRG 0.01
- HOOK -0.02
- Stochastic Oscillator
- BFRG 46.94
- HOOK 5.71
About BFRG Bullfrog AI Holdings Inc.
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Its platform technology, named, bfLEAP, is an analytical AI/ML platform that is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of its data.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.